Klotho Neurosciences CEO to Attend Inaugural Conference on Neurodegenerative Therapies
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biotechnology firm pioneering Klotho-based therapeutics for neurodegenerative diseases, has announced that its CEO, Dr. Joseph Sinkule, will participate in the inaugural Klotho Conference and Scientific Seminar. This groundbreaking event is set to be held at the UC-Irvine Beal Applied Innovation Center in Irvine, California, from September 15 to 16, 2025.
The conference aims to bring together top minds in the field to discuss the future of Klotho-based therapies and diagnostics. This first-of-its-kind seminar will feature two of the company's leading scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch, who will present their ongoing research focused on Klotho gene therapy. Their work specifically targets the treatment of ALS, Alzheimer’s disease, and the biological process of aging, highlighting the potential of Klotho to alter the landscape of neurotherapeutics.
Dr. Sinkule will be available throughout the conference to meet with investors and potential partners, providing an excellent opportunity for networking and collaboration. Those interested in participating or learning more about Klotho Neurosciences can reach out via email at [email protected].
Klotho Neurosciences, Inc. is at the forefront of biogenetics, dedicated to developing innovative disease-modifying cell and gene therapies that leverage a protein derived from a patented form of the human Klotho gene. This protein is known for its anti-aging properties and is critical in revolutionizing treatments for neurodegenerative and age-related disorders like ALS, Alzheimer’s disease, and Parkinson’s disease.
The company's current portfolio includes proprietary cell and gene therapy programs that utilize DNA and RNA as therapeutic agents, alongside genomics-based diagnostic tests. Led by an experienced team in biopharmaceutical development, Klotho aims to make substantial advancements in the medical field.
This announcement also contains forward-looking statements. These statements are subject to the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements generally include keywords like "believe," "project," "expect," "anticipate," "estimate," "intend," "strategize," and similar phrases. While these projections are based on current expectations and assumptions, they are inherently subject to risks and uncertainties. Various factors could cause actual results to differ significantly from those anticipated in these forward-looking statements, including the company's ability to execute its business plans, identify new opportunities, and meet or exceed its financial projections.
Investors and stakeholders are encouraged to take into account the aforementioned factors and the other risks detailed in documents filed by Klotho with the U.S. Securities and Exchange Commission (SEC), which may lead to significant changes in future projections. All information shared in this announcement is current as of the date of release, and the company commits to no obligation to update any forward-looking statements unless required by applicable law.
The conference aims to bring together top minds in the field to discuss the future of Klotho-based therapies and diagnostics. This first-of-its-kind seminar will feature two of the company's leading scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch, who will present their ongoing research focused on Klotho gene therapy. Their work specifically targets the treatment of ALS, Alzheimer’s disease, and the biological process of aging, highlighting the potential of Klotho to alter the landscape of neurotherapeutics.
Dr. Sinkule will be available throughout the conference to meet with investors and potential partners, providing an excellent opportunity for networking and collaboration. Those interested in participating or learning more about Klotho Neurosciences can reach out via email at [email protected].
Klotho Neurosciences, Inc. is at the forefront of biogenetics, dedicated to developing innovative disease-modifying cell and gene therapies that leverage a protein derived from a patented form of the human Klotho gene. This protein is known for its anti-aging properties and is critical in revolutionizing treatments for neurodegenerative and age-related disorders like ALS, Alzheimer’s disease, and Parkinson’s disease.
The company's current portfolio includes proprietary cell and gene therapy programs that utilize DNA and RNA as therapeutic agents, alongside genomics-based diagnostic tests. Led by an experienced team in biopharmaceutical development, Klotho aims to make substantial advancements in the medical field.
This announcement also contains forward-looking statements. These statements are subject to the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements generally include keywords like "believe," "project," "expect," "anticipate," "estimate," "intend," "strategize," and similar phrases. While these projections are based on current expectations and assumptions, they are inherently subject to risks and uncertainties. Various factors could cause actual results to differ significantly from those anticipated in these forward-looking statements, including the company's ability to execute its business plans, identify new opportunities, and meet or exceed its financial projections.
Investors and stakeholders are encouraged to take into account the aforementioned factors and the other risks detailed in documents filed by Klotho with the U.S. Securities and Exchange Commission (SEC), which may lead to significant changes in future projections. All information shared in this announcement is current as of the date of release, and the company commits to no obligation to update any forward-looking statements unless required by applicable law.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.